Beijing Danatlas Pharmaceutical Technology describes new POLθ inhibitors
June 4, 2024
Beijing Danatlas Pharmaceutical Technology Co. Ltd. has identified thiadiazolyl derivatives acting as DNA polymerase θ (POLθ, POLQ) inhibitors reported to be useful for the treatment of cancer.